|Packaging Size||400 Mg,100 Mg Injection|
|Packaging||400 Mg,100 Mg Vial|
|Treatment||Cancer It Is Given By Slow Injection Into a Vein And Used For Colon Cancer,Lung Cancer,Glioblastom|
|Dosage Form||400 Mg,100 Mg|
|Therapeutic Uses||Cancer It Is Given By Slow Injection Into a Vein And Used For Colon Cancer,Lung Cancer,Glioblastom|
|Interactions||Bevacizumab Inhibits The Growth Of Blood Vessels,Which is part of the body's normal healing and mai|
|Side Effect||Difficulty Breathing,Flushing,Severe Dizziness,Nausea/Vomiting,Shaking,Or Chest Pain.|
Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. For age related macular degeneration it is given by injection into the eye.
Common side effects when used for cancer include nose bleeds, headache, high blood pressure, and rash.Other severe side effects include gastrointestinal perforation, bleeding, allergic reactions, blood clots, and an increased risk of infection.When used for eye disease side effects can include vision loss and retinal detachment.Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor.It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF A), in other words anti VEGF therapy.
Bevacizumab was approved for medical use in the United States in 2004.It is on the World Health Organizations List of Essential Medicines, the safest and most effective medicines needed in a health system.It is listed for its use in treating eye disease.
Bevacizumab was approved in the United States in February 2004, for use in metastatic colorectal cancer when used with standard chemotherapy treatment (as first-line treatment) and with 5-fluorouracil based therapy for second line metastatic colorectal cancer.
It was approved by the European Medicines Agency (EMA) in January 2005, for use in colorectal cancer.
Also can be used some cases Lung cancer,Breast cancer,Renal cancers,Brain cancers,Eye disease,Ovarian cancer.
Bevacizumab is usually given intravenously every 14 days. In colon cancer, it is given in combination with the chemotherapy drug 5 FU (5 fluorouracil), leucovorin, and oxaliplatin or irinotecan.[medical citation needed] For treatment of eye diseases it is injected intravitreously.
Bevacizumab inhibits the growth of blood vessels, which is part of the bodys normal healing and maintenance. The body grows new blood vessels in wound healing, and as collateral circulation around blocked or atherosclerotic blood vessels.
The main side effects are hypertension and heightened risk of bleeding. Bowel perforation,Fatigue and infection are also common. In advanced lung cancer, less than half of patients qualify for treatment.Nasal septum perforation and renal thrombotic microangiopathy
Mechanism of action
Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF A). VEGF A is a growth factor protein that stimulates angiogenesis in a variety of diseases, especially in cancer.
It received its first approval, for combination use with standard chemotherapy for metastatic colon cancer.It approved for use in certain lung cancers, renal cancers, ovarian cancers, and glioblastoma multiforme of the brain.
The drug remains approved for breast cancer use in other countries including Australia.
The European Commission approved bevacizumab in combination with paclitaxel for the first line treatment of metastatic breast cancer.
In 2008, the FDA approved bevacizumab for use in breast cancer.
In 2011, the US Food and Drug Administration removed bevacizumab indication for metastatic breast cancer after concluding that the drug has not been shown to be safe and effective. The specific indication that was withdrawn was for the use of bevacizumab in metastatic breast cancer, with paclitaxel for the treatment of people who have not received chemotherapy for metastatic HER2-negative breast cancer.
- Packaging Details: 400mg , 100mg vial